OncoSil Medical

OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes by utilising the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in combination with chemotherapy. OncoSil Medicals lead product, OncoSilTM, is a brachytherapy device which has received CE Marking approval, providing marketing authorisation in both the EU and the UK. The device is approved for use in New Zealand, Hong Kong, Switzerland, Turkey and Israel. OncoSilTM is designated as a breakthrough device in both Europe and the United States1. We believe in our technology and its ability to have a truly positive impact in Oncology. OncoSilTM technology is not available in all geographies. If you are a healthcare professional, please refer to our website for information about our technology and indications. Website link: oncosil.com References: 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. M...